Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden

被引:0
作者
Åsa Ericsson
Adam Lundqvist
机构
[1] Novo Nordisk Scandinavia AB,
[2] IHE,undefined
[3] The Swedish Institute for Health Economics,undefined
来源
Applied Health Economics and Health Policy | 2017年 / 15卷
关键词
Liraglutide; Insulin Glargine; Basal Insulin; Insulin Aspart; Insulin Detemir;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:237 / 248
页数:11
相关论文
共 157 条
[31]  
Borg S(1996)United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus Ann Intern Med. 124 136-undefined
[32]  
Persson U(2004)Health and economic impact of combining metformin with nateglinide to achieve glycemic control: comparison of the lifetime costs of complications in the UK Cost Eff Resour Alloc. 2 2-undefined
[33]  
Svensson M(2016)Cost effectiveness of IDegLira vs. alternative basal insulin intensification therapies in patients with type 2 diabetes mellitus uncontrolled on basal insulin in a UK setting PharmacoEconomics. 34 953-undefined
[34]  
Peyrot M(2014)Validation of the IMS CORE diabetes model Value Health. 17 714-undefined
[35]  
Barnett AH(2016)Estimating the impact of changes in HbA1c, body weight and insulin injection regimen on health related quality-of-life: a time trade off study Health Qual Life Outcomes. 14 1-undefined
[36]  
Meneghini LF(2014)Association between glycated hemoglobin and health utility for type 1 diabetes Patient. 7 197-undefined
[37]  
Schumm-Draeger PM(undefined)undefined undefined undefined undefined-undefined
[38]  
Dushay J(undefined)undefined undefined undefined undefined-undefined
[39]  
Abrahamson MJ(undefined)undefined undefined undefined undefined-undefined
[40]  
Inzucchi SE(undefined)undefined undefined undefined undefined-undefined